Embargoed until 5:36 p.m. CT/6:36 p.m. ET, Sunday, Nov. 6, 2022
This research is scheduled to simultaneously publish in the Journal of the American College of Cardiology.
(NewMediaWire) – November 06, 2022 – CHICAGO Six widely used dietary supplements promoted for improving heart health did not effectively lower LDL or “bad” cholesterol in comparison to a common low-dose statin medication or placebo, according to late breaking science results presented today at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5-7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
“According to a 2020 market research analysis, Americans spend an estimated $50 billion on dietary supplements annually, and many are marketed for heart protection’ or cholesterol management’. Yet there is minimal-to-no research demonstrating these benefits,” said study author Luke J. Laffin, M.D., co-director of the Center for Blood Pressure Disorders at the Cleveland Clinic in Cleveland, Ohio. “Some people also believe supplements are as effective or more effective than cholesterol-lowering statin medications.”
This study compared the effectiveness of a low-dose statin to that of six common dietary supplements in lowering low-density lipoprotein (LDL) cholesterol known as bad cholesterol as well as their effects on other cholesterol levels and markers of inflammation.
There are two types of cholesterol. High-density lipoprotein (HDL) cholesterol is called the “good” cholesterol because it protects the heart. In contrast, high levels of low-density lipoprotein (LDL), the “bad” cholesterol, suggest higher risk for heart disease and stroke because it forms deposits that can narrow and stiffen arteries. Elevated bad cholesterol is a growing problem worldwide. Globally in 2020, there were 4.51 million deaths attributable to high LDL cholesterol, which was up 19% from 2010, according to American Heart Association 2022 statistics.
In this study, called Supplements, Placebo or Rosuvastatin Study, or SPORT, researchers analyzed health data for 199 adults between ages 40-75 years who had no personal history of cardiovascular disease. Participants had LDL cholesterol measures between 70 mg/dL and 189 mg/dL, and a 5%- 20% risk of developing atherosclerotic cardiovascular disease within 10 years.
Researchers randomly assigned participants to one of eight groups to track any changes in LDL cholesterol and other markers of heart disease from day one to day 28 of the study. The groups included those taking: a placebo, or sham pill; 5 mg of the low-dose statin medication rosuvastatin (a standard medication); or one of six dietary supplements (Nature Made(R) fish oil 2,400 mg; Nutriflair(TM) brand cinnamon 2,400 mg; Garlique(TM) brand garlic with 5,000 mcg of allicin; BioSchwartz brand turmeric curcumin with bioperine 4,500 mg; Nature Made(R) CholestOff Plus(TM) with 1,600 mg of plant sterols; or Arazo Nutrition brand of red yeast rice 2,400 mg).
“Although there are prior studies demonstrating that red yeast rice and plant sterol supplements may reduce LDL cholesterol, the findings of our study underscore that the contents of these dietary supplements may vary. Therefore, they do not produce consistent reductions in cholesterol,” Laffin said. “This study sends an important public health message that dietary supplements commonly taken for cholesterol health’ or heart health’ are unlikely to offer meaningful impact on cholesterol levels. The results also indicate that a low-dose statin offers important beneficial effects on one’s cholesterol profile. Future research should study other types of dietary supplements and their potential impact on cholesterol levels.”
The American Heart Association in its 2018 Cholesterol Guidelines emphasizes a heart-healthy lifestyle throughout life. In addition, the association suggests people not rely on supplements and recommends that healthy people get adequate nutrients by eating a variety of foods in moderation. Moreover, the Association recommends physical activity is the optimal first treatment choice for adults with mild to moderately elevated blood pressure and blood cholesterol who otherwise have low heart disease risk
A limitation of the study is that its duration was only 28 days, which was long enough to demonstrate a reduction in LDL cholesterol with the statin medication. “However, it is unknown if some of the supplements may require a longer time to have any effect on cholesterol,” according to Laffin.
Co-authors are Dennis Bruemmer, M.D.; Michelle Garcia, R.N.; Danielle Brennan, M.S.; Ellen McErlean, M.S.N.; Douglas Jacoby, M.D.; Erin D. Michos, M.D., M.H.S, FAHA; Paul M. Ridker, M.D., FAHA; Tracy Y. Wang, M.D., M.H.S., M.S., FAHA; Karol E. Watson, M.D., Ph.D., FAHA; Howard Hutchinson, M.D.; and Steven E. Nissen, M.D. Authors’ disclosures are listed in the abstract.
The study was funded by AstraZeneca.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
The American Heart Association’s Scientific Sessions 2022 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates occurring Saturday through Monday, November 5-7, 2022. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2022 on social media via #AHA22.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective:
AHA Communications & Media Relations in Dallas: 214-706-1173; [email protected]
Bridgette McNeill: 214-704-1135; [email protected]
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org